Clinical Trial Update: Bezlotoxumab Efficacy and Tolerability in Cancer Patient [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating bezlotoxumab for preventing recurrent Clostridioides difficile infection in cancer patients, focusing on efficacy and tolerabili…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection Recurrence

Drugs mentioned

• Bezlotoxumab (bezlotoxumab)

Snippet

Sponsor: The Cooper Health System | Conditions: Clostridium Difficile Infection Recurrence | Phase 4 | Status: UNKNOWN